DeepMed Research

Traws Pharma, Inc.

🇺🇸United States

Country: 🇺🇸United States

Ownership: Public

Established: 1998-01-01

Employees: 17

Market Cap: -

Website: http://www.trawspharma.com

Clinical Trials

A Clinical Study Aiming to Assess Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of TRX-100 in Healthy Volunteers

Phase 1

Recruiting

Conditions: Healthy Volunteer Study

Interventions: Drug: TRX-100
Drug: Placebo

First Posted Date: 2025-01-03

Last Posted Date: 2025-01-03

Lead Sponsor: Traws Pharma, Inc.

Target Recruit Count: 32

Registration Number: NCT06757738

Locations: 🇦🇺
Scientia Clinical Research, Sydney, Greater Sydney Area, Australia

Evaluation Safety, Tolerability, and Pharmacokinetics of Single and Multiple Ascending Doses of 83-0060 in Healthy Volunteers

Phase 1

Recruiting

Conditions: Healthy Volunteers Only

Interventions: Drug: 83-0060
Drug: Placebo

First Posted Date: 2024-05-07

Last Posted Date: 2024-10-14

Lead Sponsor: Traws Pharma, Inc.

Target Recruit Count: 64

Registration Number: NCT06402136

Locations: 🇦🇺
Scientia Clinical Research, Sydney, Greater Sydney Area, Australia

Study of Narazaciclib (ON 123300) Plus Letrozole in Endometrial Cancer and Other Gynecologic Malignancies

Phase 1

Recruiting

Conditions: Endometrioid Endometrial Cancer

Interventions: Drug: Narazaciclib
Drug: Letrozole 2.5mg

First Posted Date: 2023-01-30

Last Posted Date: 2023-12-12

Lead Sponsor: Traws Pharma, Inc.

Target Recruit Count: 60

Registration Number: NCT05705505

Locations: 🇺🇸
NYU Langone, New York, New York, United States
🇺🇸
Texas Oncology-Baylor Charles A. Sammons Cancer Center, Dallas, Texas, United States
🇺🇸
Arizona Oncology Associates, PC - HOPE, Tucson, Arizona, United States

and more 5 locations

Study of ON 123300 in Patients With Advanced Cancer

Phase 1

Recruiting

Conditions: Solid Tumors, Adult

Interventions: Drug: ON123300

First Posted Date: 2021-02-04

Last Posted Date: 2023-12-07

Lead Sponsor: Traws Pharma, Inc.

Target Recruit Count: 36

Registration Number: NCT04739293

Locations: 🇺🇸
Mary Crowley Cancer Research, Dallas, Texas, United States
🇺🇸
Greenville Health System, Institute for Oncology Clinical Research, Greenville, South Carolina, United States
🇺🇸
START Midwest, Grand Rapids, Michigan, United States

Controlled Study of Rigosertib Versus Physician's Choice of Treatment in MDS Patients After Failure of an HMA

Phase 3

Terminated

Conditions: Myelodysplastic Syndrome
RAEB
Refractory Anemia With Excess Blasts
MDS

Interventions: Drug: Any approved or standard-of-care therapy
Drug: rigosertib
Drug: best supportive care (BSC)

First Posted Date: 2015-09-29

Last Posted Date: 2022-09-26

Lead Sponsor: Traws Pharma, Inc.

Target Recruit Count: 372

Registration Number: NCT02562443

Locations: 🇺🇸
New York Medical College, Valhalla, New York, United States
🇺🇸
USC Norris Comprehensive Cancer Center, Los Angeles, California, United States
🇺🇸
University of Maryland Greenebaum Cancer Center, Baltimore, Maryland, United States

and more 155 locations

Dose-escalation, Safety and Pharmacokinetic Study of Briciclib in Advanced Solid Tumors

Phase 1

Terminated

Conditions: Neoplasms
Advanced Solid Tumor

Interventions: Drug: briciclib

First Posted Date: 2014-06-20

Last Posted Date: 2021-06-22

Lead Sponsor: Traws Pharma, Inc.

Target Recruit Count: 26

Registration Number: NCT02168725

Locations: 🇺🇸
University of Colorado Hospital Anschutz Medical Campus, Aurora, Colorado, United States
🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States
🇺🇸
Sarah Cannon Research Institute, Nashville, Tennessee, United States

Platinum-based Chemoradiotherapy and Rigosertib in Head and Neck Cancer

Phase 1

Completed

Conditions: Head and Neck Neoplasms
Carcinoma, Squamous Cell

Interventions: Drug: oral rigosertib
Drug: cisplatin
Radiation: Radiotherapy

First Posted Date: 2014-04-08

Last Posted Date: 2017-06-23

Lead Sponsor: Traws Pharma, Inc.

Target Recruit Count: 2

Registration Number: NCT02107235

Locations: 🇺🇸
University of Colorado Cancer Center, Aurora, Colorado, United States
🇺🇸
The Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
🇺🇸
Christiana Care Health Services, Newark, Delaware, United States

and more 1 locations

Three Dosing Schedules of Oral Rigosertib in MDS Patients

Phase 1

Withdrawn

Conditions: Myelodysplastic Syndrome

Interventions: Drug: rigosertib

First Posted Date: 2014-03-03

Last Posted Date: 2020-07-01

Lead Sponsor: Traws Pharma, Inc.

Registration Number: NCT02075034

Locations: 🇺🇸
Columbia University Medical Center, New York, New York, United States

Metabolism and Excretion of [14C]-Rigosertib After Infusion to Volunteers

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: rigosertib

First Posted Date: 2014-01-08

Last Posted Date: 2017-06-23

Lead Sponsor: Traws Pharma, Inc.

Target Recruit Count: 6

Registration Number: NCT02030639

Locations: 🇺🇸
Covance Clinical Research Unit, Inc., Madison, Wisconsin, United States

Efficacy and Safety of IV Rigosertib in MDS Patients With Excess Blasts Progressing After Azacitidine or Decitabine

Phase 3

Completed

Conditions: Myelodysplastic Syndromes
Cytopenia
Refractory Anemia With Excess Blasts
Chronic Myelomonocytic Leukemia

Interventions: Drug: rigosertib sodium

First Posted Date: 2013-08-26

Last Posted Date: 2020-06-30

Lead Sponsor: Traws Pharma, Inc.

Target Recruit Count: 67

Registration Number: NCT01928537

Locations: 🇺🇸
Stanford University Cancer Center, Stanford, California, United States
🇺🇸
Mount Sinai Medical Center, New York, New York, United States
🇺🇸
Mayo Clinic, Rochester, Minnesota, United States

and more 32 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy